Literature DB >> 25978959

Therapeutic effects of hybrid liposomes with downregulation of inflammatory cytokine for model mice of rheumatoid arthritis in vivo.

Hideaki Ichihara1, Shuichi Yamasaki1, Motoki Hino1, Ryuichi Ueoka1, Yoko Matsumoto2.   

Abstract

Therapeutic effects of HL for a collagen-induced arthritis (CIA) mouse models of HL-23 composed of 95mol% l-α-dimyristoylphosphatidylcholine (DMPC) and 5mol% polyoxyethylenedodecylether (C12(EO)23) in vivo were examined. Remarkably high therapeutic effects of HL-23 for CIA mouse models were obtained on the basis of clinical assessment of arthritis. The reduction of hyperplastic synovial membrane (pannus tissue) and destruction of the cartilage and bone by HL-23 was revealed on the basis of hematoxylin and eosin (HE) and safranin O staining. Furthermore, the downregulation of inflammatory cytokines such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6 for CIA mouse models treated with HL-23 were investigated. Remarkably high therapeutic effects without joint swelling were obtained in CIA mouse models treated with HL-23.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Collagen-induced arthritis mouse models; Hybrid liposomes; In vivo; Rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 25978959     DOI: 10.1016/j.bmcl.2015.04.083

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Paeoniflorin ameliorates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2.

Authors:  Zhilin Jia; Jiao He
Journal:  Exp Ther Med       Date:  2015-12-02       Impact factor: 2.447

2.  [Efficacy of internalized RGD-modified echogenic liposomes in diagnosis and treatment in a mouse model of rheumatoid arthritis].

Authors:  Zhen Gan; Hao Wu; Hao-Han Wu; Mei-Jun Zhou; Fei Yan; Hong-Mei Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.